PathMaker Neurosystems Inc. Receives Expedited Access Pathway Designation From FDA For MyoRegulator
PathMaker Neurosystems'MyoRegulatorPM-2200 system has received Expedited Access Pathway (EAP) designation and priority processing status from the U.S. Food and Drug Administration (FDA). MyoRegulator is PathMaker’s first product, and is being developed for the treatment of muscle spasticity found in patients with stroke, cerebral palsy (CP), multiple sclerosis (MS), spinal cord injury (SCI), traumatic brain injury (TBI) and numerous other neurological conditions.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news
More News: Brain | Cerebral Palsy | Food and Drug Administration (FDA) | Medical Devices | Multiple Sclerosis | Neurology | Spinal Cord Injury | Stroke